<DOC>
	<DOCNO>NCT02495766</DOCNO>
	<brief_summary>This study evaluate effect cryopreserved autologous adult bone-marrow mesenchymal stromal cell ( BM-MSC ) patient active multiple sclerosis , compare placebo . Patients allocate one 2 treatment arm ( BM-MSC placebo ) month 6 , treatment cross receive product . The objective ass safety single infusion BM-MSC , explore efficacy patient . Patients evaluate month 12 followed-up total 3 year .</brief_summary>
	<brief_title>Autologous Mesenchymal Stromal Cells Multiple Sclerosis</brief_title>
	<detailed_description>To date , effective therapy cure multiple sclerosis ( MS ) . Immunomodulatory therapy useful reduce frequency inflammatory process ( relapse ) n't delay significantly progression disease , prevent long term disability induce repair damage tissue . This proposal contemplate use adult autologous bone marrow mesenchymal stromal cell ( BM-MSC ) alternative therapeutic strategy treat patient active MS . This randomized , double blind , crossover clinical trial 8 patient active form MS moderate disability enter trial primary objective assess safety tolerability single intravenous infusion BM-MSC . Secondary objective assess efficacy gadolinium enhance lesion though magnetic resonance imaging , neurophysiological effect immunological effect . Once randomize , patient undergo BM extraction confirm availability need dose , randomize one 2 treatment arm ( BM-MSC name XCEL-MC-ALPHA , placebo ) . XCEL-MC-ALPHA cryopreserved patient regardless allocate arm . At month 6 , treatment cross . Patients evaluate month 12 followed-up total 3 year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Patients 18 60 year age Patients MS Relapsingremitting secondary progressive MS Patients indicated position initiate treatment diseasemodifying drug Expanded Disability Status Scale ( EDDS ) score &lt; 6.5 Nine T2 lesion least Active multiple sclerosis define either 1 outbreak last year least one Gadoliniumenhancing lesion last 6 month Signed informed consent form Interferon beta glatiramer acetate 3 month prior screen Natalizumab fingolimod 6 month prior screen Mitoxantrone , cyclophosphamide immunosuppressive therapy time Has receive experimental treatment within 3 month prior screen MS outbreak within 4 week prior randomization Serum creatinine &gt; 2.0 mg/dl Infectious disease active uncontrolled Fertile patient use suitable method contraception Pregnant lactate woman Immunodeficiency Positive serology HIV , Hepatitis B , Hepatitis C syphilis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Bone marrow mesenchymal stromal cell</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
	<keyword>Autoimmune Diseases</keyword>
</DOC>